Objectives: Olfactory dysfunction is one of the most recognized symptoms of COVID-19, significantly impacting quality of life, particularly in cases where recovery is prolonged. This review aims to explore patterns of olfactory recovery post-COVID-19 infection, with particular focus on delayed recovery.

Data Sources: Published literature in the English language, including senior author's own work, online and social media platforms, and patients' anecdotal reports.

Method: A comprehensive review of the literature was undertaken by the authors with guidance from the senior author with expertise in the field of olfaction.

Results: Based on self-report, an estimated 95% of patients recover their olfactory function within 6 months post-COVID-19 infection. However, psychophysical testing detects higher rates of persistent olfactory dysfunction. Recovery has been found to continue for at least 2 years postinfection; negative prognostic indicators include severe olfactory loss in the acute phase, female sex, and older age. Variability in quantitative and qualitative disturbance in prolonged cases likely reflects both peripheral and central pathophysiological mechanisms. Limitations of many of the reviewed studies reflect lack of psychophysical testing and baseline olfactory assessment.

Conclusions: Post-COVID-19 olfactory dysfunction remains a significant health and psychosocial burden. Emerging evidence is improving awareness and knowledge among clinicians to better support patients through their olfactory rehabilitation, with hope of recovery after several months or years. Further research is needed to better understand the underlying pathogenesis of delayed recovery, identify at risk individuals earlier in the disease course, and develop therapeutic targets.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11156684PMC
http://dx.doi.org/10.1002/wjo2.163DOI Listing

Publication Analysis

Top Keywords

olfactory dysfunction
16
olfactory
9
post-covid-19 infection
8
psychophysical testing
8
recovery
6
recovery rates
4
rates long-term
4
long-term olfactory
4
dysfunction
4
dysfunction covid-19
4

Similar Publications

In patients with severe olfactory and gustatory dysfunction, olfactory cleft opacification improves with expanded intranasal steroid treatment (EDS-FLU) relative to placebo. This is directly associated with objective and patient-reported taste/smell improvement.

View Article and Find Full Text PDF

Background: Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are prevalent disease complications in people with cystic fibrosis. These understudied comorbidities significantly impact quality of life. The impact of highly effective modulator therapy (HEMT) in young children with cystic fibrosis (YCwCF) on these disease complications is unknown.

View Article and Find Full Text PDF

This study aimed to investigate the topological properties of brain functional networks in patients with tinnitus of varying durations. A total of 51 tinnitus patients (divided into recent-onset tinnitus (ROT) and persistent tinnitus (PT) groups) and 27 healthy controls (HC) were recruited. All participants underwent resting-state functional MRI and audiological assessments.

View Article and Find Full Text PDF

Target odorant detection in mixtures has been shown to become more difficult as the number of background odorants increases and falls below chance level in mixtures with 16 components. Our aim was to investigate target odorant detection in mixtures among healthy people and compare it between dysosmic patients and age- and gender-matched controls. Participants underwent extensive olfactory testing and performed two target odorant detection tasks.

View Article and Find Full Text PDF

Objectives: Parkinson's disease (PD) is characterized by olfactory dysfunction (OD) and cognitive deficits at its early stages, yet the link between OD and cognitive deficits is also not well-understood. This study aims to examine the changes in the olfactory network associated with OD and their relationship with cognitive function in de novo PD patients.

Methods: A total of 116 drug-naïve PD patients and 51 healthy controls (HCs) were recruited for this study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!